Impact of GLP-1 Receptor Agonists on Bone Metabolism

CONTEXT: Glucagon-like peptide-1 receptor agonists (GLP-1RAs), used to treat type 2 diabetes mellitus (T2DM) and obesity, have shown multi-organ benefits. However, their effects on bone are uncertain. GLP-1RAs may favor skeletal health through improved metabolic control, but substantial weight loss may increase bone loss and fracture risk. Understanding this balance between benefit and risk is an important clinical priority. EVIDENCE ACQUISITION: This mini-review summarizes the current evidence on the effects of GLP-1RAs on bone health and skeletal metabolism in individuals with type 2 diabetes and obesity, as informed by a literature search using the PubMed and Embase databases. EVIDENCE SYNTHESIS: Preclinical data generally support a beneficial role for GLP-1 signaling in bone, with evidence for enhanced osteoblast activity, reduced bone resorption, and improved bone mass and strength. In people with T2DM, GLP-1RAs appear neutral to modestly beneficial for BMD and bone remodeling. In those without T2DM, greater weight loss is more consistently associated with declines in BMD and increases in bone turnover. However, clinical studies to date have had relatively short follow-up and limited focus on skeletal endpoints. Additionally, newer agents associated with greater weight loss are underrepresented in the data. CONCLUSION: Current evidence suggests that GLP-1RAs may directly benefit bone health, but these benefits may be offset by weight-loss-related skeletal risks, particularly in nondiabetic and high-risk individuals. Additional research is needed to define their true impact on bone depending on clinical context. These findings will guide strategies that preserve skeletal health while maintaining GLP-1 RAs' metabolic benefits.